A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

Evidence suggests that combining immunotherapy with hypomethylating agents may enhance antitumor activity. This phase 2 study investigated the activity and safety of durvalumab, a programmed death-ligand 1 (PD-L1) inhibitor, combined with azacitidine for patients aged ≥65 years with acute myeloid le...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeidan, Amer M., Boss, Isaac, Beach, C. L., Copeland, Wilbert B., Thompson, Ethan, Fox, Brian A., Hasle, Vanessa E., Hellmann, Andrzej, Taussig, David C., Tormo, Mar, Voso, Maria Teresa, Cavenagh, James, O’Connor, Tim, Previtali, Alessandro, Rose, Shelonitda, Silverman, Lewis R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006260/
https://www.ncbi.nlm.nih.gov/pubmed/34933333
http://dx.doi.org/10.1182/bloodadvances.2021006138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006260/
https://www.ncbi.nlm.nih.gov/pubmed/34933333
http://dx.doi.org/10.1182/bloodadvances.2021006138

Ejemplares similares